Article Details

Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4 ...

Retrieved on: 2022-09-11 00:27:34

Tags for this article:

Click the tags to see associated articles and topics

Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4 .... View article details on HISWAI: https://www.precisiononcologynews.com/cancer/lillys-verzenio-extends-five-year-breast-cancer-survival-adds-debate-over-best-cdk46

Excerpt

By contrast, Pfizer's Ibrance did not improve overall survival versus placebo in the same first-line advanced breast cancer setting in the Phase III ...

Article found on: www.precisiononcologynews.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up